U.S. Hospitality Stock News

The United States market has experienced a 2.3% increase over the last week and a significant 25% rise in the past year, with earnings projected to grow by 19% annually. In such an environment, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation amidst robust market growth.

Over the last 7 days, the United States market has risen by 2.3%, contributing to a robust 25% increase over the past year, with earnings forecasted to grow by 19% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its potential for future success.

The United States market has experienced a robust climb, with a 2.3% increase in the last week and a significant 25% rise over the past year, while earnings are projected to grow by 19% annually. Amidst these favorable conditions, identifying stocks that combine affordability with growth potential is key, especially when considering penny stocks. Although the term 'penny stock' might seem outdated, these smaller or newer companies can still offer substantial opportunities for investors who...

Recent analyst coverage of Parker-Hannifin (PH), including a new positive rating from Bernstein and an upside catalyst watch from Citi, has coincided with renewed interest following bullish technical signals in the stock. See our latest analysis for Parker-Hannifin. At a share price of $938.51, Parker-Hannifin has seen momentum pick up recently, with a 1-month share price return of 8.79% and a year-to-date share price return of 4.98%. Over the longer term, total shareholder returns of 45.15%...

US manufacturing stocks are back in focus as fresh tariff proposals, trade investigations, and the prospect of a new US-China Board of Trade reshape expectations for supply chains and costs. For investors, the question is which US Domestic Manufacturing Stocks could potentially benefit from this policy turn and which might face pressure as trade relationships evolve. This article highlights 3 stocks from the screener that are directly exposed to these trade headlines, explaining how the same...

Earlier in June 2026, Bruker Corporation filed an omnibus shelf registration covering a wide range of securities and showcased expanded infectious disease diagnostics capabilities, including new FDA-cleared enhancements for its MALDI Biotyper CA System and advanced workflows for rapid antimicrobial susceptibility testing. By pairing a broad financing toolkit with an enlarged microbiology and molecular diagnostics portfolio, Bruker is signaling both product ambition and flexibility in how it...

W.W. Grainger (GWW) has drawn attention after recent trading, with the stock last closing at $1,319.72. Investors are weighing this move against its recent performance and the company’s current fundamentals. See our latest analysis for W.W. Grainger. Recent trading in W.W. Grainger sits against a backdrop of strong momentum, with a 30 day share price return of 3.71% and a 90 day share price return of 26.19%, while the 5 year total shareholder return of 213.89% points to a robust longer term...

Agios Pharmaceuticals (AGIO) stock is back in focus after the company shared detailed 52 week data from its RISE UP Phase 3 trial of mitapivat in sickle cell disease at EHA 2026. See our latest analysis for Agios Pharmaceuticals. Agios Pharmaceuticals shares have recently picked up momentum, with a 7 day share price return of 10.25% and a 30 day share price return of 12.87%. However, the 1 year total shareholder return is still down 10.31%, showing short term enthusiasm against a mixed longer...

Recent commentary around Halozyme Therapeutics (HALO) has centered on its collaborations with large pharmaceutical partners and its use of recombinant human hyaluronidase technology to broaden injectable biologic delivery and expand global reach. See our latest analysis for Halozyme Therapeutics. Recent updates around Medicare drug price negotiations and technical trading signals have coincided with Halozyme Therapeutics’ 10.07% 90 day share price return and a 31.03% 1 year total shareholder...

LPL Financial Holdings (LPLA) has drawn fresh attention after reporting May 2026 metrics that showed 3.1% growth in total client assets, with advisory assets reaching 60.2% of the total, alongside $8.8 billion in organic net new assets. See our latest analysis for LPL Financial Holdings. The recent May asset update and the addition of new advisory teams have come alongside a 6.29% 90 day share price return, even as the year to date share price return is down 16.13% and the 1 year total...

If you are wondering whether Eli Lilly stock still offers reasonable value after its huge run, this article will walk through what the current price might be implying. The stock trades around US$1,122.50, with returns of 11.7% over the past month, 3.9% year to date, 42.9% over the past year, very large gains over three years and around 7x over five years. This naturally raises questions about growth expectations and risk. Recent headlines around Eli Lilly have centered on its position in...

On 10 June 2026, GitLab expanded its collaboration with Google Cloud to offer a managed, sovereign DevSecOps platform and unveiled new AI-powered features like Next Generation Source Code Management, GitLab Orbit, and enhanced agent governance to support large-scale, compliant software delivery. A distinctive angle is GitLab’s push to combine fast, token-efficient AI agents with fine-grained security and compliance controls, directly targeting heavily regulated enterprises that need both...

Macerich (MAC) stock has drawn investor attention after its recent performance, with the share price closing at $23.75 and total return figures highlighting a mix of shorter and longer term outcomes. See our latest analysis for Macerich. Recent trading has been choppy for Macerich, with the share price falling 5.34% over the last day even after a 30 day share price return of 9.95% and a year to date share price return of 28.24%. The 1 year total shareholder return of 55.45% and 3 year total...

Dynatrace (DT) is back in focus after multiple major banks, including UBS, initiated or upgraded coverage with positive commentary on its AI observability platform and potential for improved revenue performance. See our latest analysis for Dynatrace. The recent upgrades have come alongside a 30 day share price return of 8.08% and a 90 day share price return of 3.03%, even as the 1 year total shareholder return is down 25.83%. This indicates near term momentum against a weaker longer term...

Benchmark's Benjamin Klieve recently reiterated a positive view on Andersons (ANDE) and raised earnings estimates after management outlined a supportive macro backdrop and growth opportunities during a non-deal roadshow with investors. See our latest analysis for Andersons. At a share price of $69.21, Andersons has given investors a year to date share price return of 30.46%, while its 1 year total shareholder return of 89.30% and 5 year total shareholder return of 150.23% point to momentum...

Deere recently reported a strong first-quarter performance, with revenues surpassing analysts’ expectations and especially strong results in its Small Agriculture and Construction & Forestry divisions. At the same time, a US$99 million settlement over repair restrictions and investor commentary on an improving downcycle backdrop underscored how Deere’s diversified model and evolving customer relationships are shaping its longer-term business profile. We’ll now explore how Deere’s...

Earlier this month, CRISPR Therapeutics AG filed a shelf registration for up to US$969.16 million in common shares tied to an ESOP-related offering, while shareholders approved amendments to the company’s articles of association at the June 4, 2026 annual meeting. Against a backdrop of earnings estimate revisions, revenue growth expectations, and a valuation premium versus peers, these capital and governance moves come as investors reassess CRISPR Therapeutics’ long‑term profile and...

Red Rock Resorts (RRR) stock drew attention after recent trading data showed a move of about 18% over the past month, prompting investors to reassess the Las Vegas-focused casino operator’s current valuation. See our latest analysis for Red Rock Resorts. That recent 18.4% 30 day share price return sits against a more mixed picture, with the share price roughly flat year to date while the 1 year total shareholder return of 24.6% points to momentum that has played out over a longer horizon. If...

MBX Biosciences (MBX) has drawn fresh attention after publishing full Phase 2 Avail and one-year open-label data for its lead candidate canvuparatide in chronic hypoparathyroidism, alongside confirming plans for a pivotal Phase 3 trial. See our latest analysis for MBX Biosciences. Against this backdrop, MBX Biosciences stock has seen strong momentum, with a 7 day share price return of 29.36% and a 90 day share price return of 41.01%, while the 1 year total shareholder return is very large at...

L3Harris Technologies (LHX) stock is under the spotlight after the company was selected by the U.S. Army for a VAMPIRE counter Unmanned Systems contract worth up to US$106 million. See our latest analysis for L3Harris Technologies. At a share price of US$310.45, L3Harris Technologies has seen a 1-year total shareholder return of 25.76% and a 3-year total shareholder return of 68.66%. Over the same period, the 90-day share price return declined 15.73%, suggesting recent weakness contrasts with...

Why Douglas Dynamics Stock Is Back on Investors' Radar Douglas Dynamics (PLOW) has drawn fresh attention after being added to the Zacks Rank #1 list, following a 15.4% increase in earnings estimates and recent strong quarterly results. See our latest analysis for Douglas Dynamics. At a share price of $47.26, Douglas Dynamics has seen momentum build, with a 30-day share price return of 6.83%, a 90-day share price return of 15.66%, and a 1-year total shareholder return of 69.38%, supported by...

In the past week, EZCORP drew higher trading interest as investors reacted to expectations for upcoming quarterly earnings of US$0.39 per share and projected revenue of US$405 million, both seen higher than the prior year. This shift in sentiment highlights how earnings and revenue forecasts can quickly reshape perceptions of EZCORP’s operating momentum and business trajectory. We’ll now examine how these stronger earnings and revenue expectations could influence EZCORP’s investment...

SiTime (SITM) is back in focus after fresh news on its timing systems for AI and data center uses, combined with expanded enterprise AI deployments and a debate over potential overvaluation. See our latest analysis for SiTime. SiTime's recent AI and data center headlines arrive after a sharp 99.21% 90 day share price return and a 210.40% 1 year total shareholder return. At the same time, the 30 day share price return declined 11.52%, which hints that momentum has cooled in the very short term...

Avis Budget Group recently confronted its strained finances by issuing US$650.00 million of asset-backed securities to fund and refinance its U.S. vehicle fleet, against a backdrop of high leverage, cumulative losses, and a Ba3 credit rating with a negative outlook from Moody’s. The combination of sustained losses, negative shareholders’ equity, and reliance on secured funding highlights a business model under pressure from refinancing risk and margin erosion. We’ll now examine how Avis...